Millennium Pharmaceuticals news from FierceBiotech
NewsDespite layoffs, scientists in high demand
Good news for scientists and researchers: despite a number of layoffs and hiring freezes, there is still high demand in the biotech industry. And human resources managers are going above and beyond... Read more...
Takeda gains RNAi tech with $1B Alnylam deal
Takeda's quest to expand in the U.S. market--and off-set expiring patents on big drugs--continues. The Japanese company announced today a $1 billion alliance with RNAi company Alnylam. The deal... Read more...
Millennium's Levin uses golden touch to fund start-up
Mark Levin earned a reputation for a colorful personality with an incredible knack for raising cash as co-founder of Millennium Pharmaceuticals. Two weeks ago, Takeda helped seal Levin's reputation... Read more...
Mass. biotechs ripe for buyouts
Recently, GSK forked over $720 million for Sirtris Pharmaceuticals and Japan's Takeda made an
ALSO NOTED: AIDS vaccine researchers years away from success; Amgen reports earnings; and much more...
> Following a series of major setbacks trying to develop a vaccine for AIDS, pessimistic researchers say they're years away from success.
Takeda makes $8.8B bid for Millennium
Looking to expand out of a budget-bound Japanese market, Takeda is taking a big chunk of its $10 billion war chest and offering $8.8 billion in cash for U.S.-based
Takeda makes $8.8B bid for Millennium
Looking to expand out of a budget-bound Japanese market, Takeda is taking a big chunk of its $10 billion war chest and offering $8.8 billion in cash for U.S.-based
Millennium chief scientist takes offbeat approach
The Scientist profiles Millennium Pharmaceuticals CSO Joe Bolen, whose team has been advancing a new therapy that targets molecules "upstream" from Velcade. The data will be released at... Read more...
ALSO NOTED: Genentech options Exelixis inhibitor; Millennium reports positive data for cancer cocktail; Immtech CEO takes a pay
> Exelixis announced that Genentech has exercised an option to develop Exelixis' XL518, a selective inhibitor of MEK which is currently in a Phase I clinical trial. Exelixis earns $3 million on... Read more...
Millennium spent $1.3M on lobbying
According to public records, Millennium Pharmaceuticals spent $1.3 million in 2007 lobbying the federal government on patent reform and biotech drug regulation. A bill--currently in the Senate--had... Read more...
| Press ReleasesPRESS RELEASE: FDA Expands Millennium Pharmaceuticals's VELCADE for Injection Label for Patients with Multiple Myeloma FDA Expands Millennium Pharmaceuticals's VELCADE for Injection Label for Patients with Multiple Myeloma, Underscores Benefit for Patients with Kidney Impairments CAMBRIDGE, Mass., Oct. 15 -- Read more >> PRESS RELEASE: Phase III Trial in Multiple Myeloma Stopped Early Due to Significant Efficacy Advantage of VELCADE Phase III Clinical Trial in Newly Diagnosed Multiple Myeloma Stopped Early Due to Highly Significant Efficacy Advantage of VELCADE for Injection Based Therapy Across All Endpoints - Millennium on Read more >> |
Paid Research Reports
- Leading Drug Delivery Companies and Technologies: Competitive landscape, company profiles and technological developments
- Drug Repositioning Strategies - Serendipity by design
- eHealthInsight Series: Online Patient Recruitment Strategies - Optimizing the clinical trial process
- Pricing & Reimbursement - Seven Major Markets Update
- Innovative Clinical Trial Design and Management: Trends, success stories and impact upon R&D budgets
